Open AccessNivolumab (Opdivo) in combination with Ipilimumab (Yervoy)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.168
Subject(s) - ipilimumab , nivolumab , reimbursement , medicine , drug , oncology , pharmacology , immunotherapy , cancer , health care , economics , economic growth
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses nivolumab (Opdivo) 10 mg/mL for injection; administered by IV infusion and ipilimumab (Yervoy) 5 mg/mL for injection; administered by IV infusion
Indication: Nivolumab (Opdivo) in combination with ipilimumab (Yervoy) is indicated for the treatment of adult patients with unresectable MPM who have not received prior systemic therapy for MPM